Consistent with our and other’s published studies delineating the role of AnxA2 in PDA neoplastic cells, Takano et al previously demonstrated that high expression of AnxA2 on the tumor cell surface (defined as >30% of tumor cells with positive staining) was correlated with rapid recurrence after adjuvant gemcitabine chemotherapy including decreased disease-free and overall survival in patients with resected PDA [22]. This evidence concerns the gene ANXA2 and Patent ductus arteriosus.